Data regarding treatment of rare invasive fungal diseases (IFDs) are scarce. We documented the efficacy and safety of isavuconazole for treatment of uncommonly diag- This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
| INTRODUC TI ON
Invasive fungal disease (IFD) is a major cause of morbidity and mortality in immunocompromised individuals, including patients with haematological malignancies or those who have undergone solid organ or haematopoietic-cell transplantations. 1 Although treatments exist for the most prevalent mould pathogens such as Aspergillus spp., treatment options are more limited for IFDs caused by rare moulds such as mucormycosis, hyalohyphomycosis and phaeohyphomycosis, which are becoming increasingly common. [2] [3] [4] The limited clinical experience with many of these rare pathogens limits the evidence to support treatment recommendations. [5] [6] [7] [8] Amphotericin B formulations are frequently used empirically when identification of an invasive fungal pathogen may be delayed or is not possible. 9, 10 However, the limited tolerability and intravenous-only administration of amphotericin B formulations can restrict their usefulness 11 and IFD caused by pathogens such as Fusarium, Scedosporium and Scopulariopsis spp. are frequently resistant to amphotericin B. [12] [13] [14] Voriconazole is clinically useful for treatment of invasive aspergillosis (IA) and certain mould and Candida infections, but it has limited activity against other fungal species such as Mucorales. 15 As yet, no antifungal agent has been demonstrated to have reliable activity against certain Paecilomyces or Scopulariopsis spp.
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Isavuconazonium sulphate is the prodrug of isavuconazole, a broad-spectrum antifungal agent, available in oral and intravenous
formulations, that has activity against a variety of fungal pathogens in vitro and in vivo. 16 In the Phase III SECURE trial, isavuconazole was non-inferior to voriconazole in adults for the treatment of IA and was associated with fewer drug-related treatment-emergent adverse events (TEAEs). 17 In patients with mucormycosis enrolled in the Phase III VITAL trial, the efficacy of isavuconazole treatment in adults was similar to that of amphotericin B in case-matched controls. 18 Based on those results, isavuconazole has been approved by the US Food and Drug Administration for primary treatment of IA and of invasive mucormycosis in adults. 19 The European Commission has approved isavuconazole in adults for the primary treatment of IA and for treatment of mucormycosis when treatment with amphotericin B is not appropriate.
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Patients enrolled in the VITAL trial also included those with IFD caused by other rare fungal species (i.e. pathogens other than
Aspergillus fumigatus or Candida species). The clinical activity of isavuconazole against Cryptococcus and dimorphic fungi among patients who participated in the VITAL trial was recently reported.
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In this article, we present the results for patients infected with other rare fungal species or unspecified fungal pathogens.
| ME THODS

| Trial design
The VITAL trial was a Phase III, single-arm, open-label study performed in 34 centres worldwide to evaluate the efficacy and safety of isavuconazole in the treatment of IA in patients with renal impairment, and in the treatment of IFDs caused by rare fungal species (ClinicalTrials.gov identifier: NCT00634049). Further details of the methods are provided in an accompanying manuscript, 22 and both methods and results for patients with IFDs caused by Mucorales spp., Cryptococcus spp. and dimorphic fungi, and more than one fungal species have been reported elsewhere. 18, 22, 23 The subsets of patients with IFDs caused by rare moulds, non-Candida yeast, and moulds not otherwise specified (NOS; IFD diagnosed on the basis of histological/cytological evidence) are presented here. The study was conducted in accordance with the Declaration of Helsinki (2000) and the International Conference on Harmonisation Guidelines for Good Clinical Practice. The study was approved by the institutional review board at each study centre and all patients provided written informed consent prior to enrolment. 
| Patients and treatment
| Assessments
An independent data-review committee verified all IFD diagnoses and assessed the primary and secondary study endpoints. methodologies. [25] [26] [27] [28] Baseline characteristics, efficacy outcomes and TEAEs that commenced within 28 days of the last dose of isavuconazole were summarised using descriptive statistics.
| RE SULTS
In total, 26 patients from the VITAL trial were included in these analyses. Baseline demographics and characteristics are presented in All values shown are n (%). Study days are relative to the first dose of isavuconazole (Day 1), which follows Day -1 (there was no Day 0). Patients with no postbaseline radiology data who had baseline evidence of radiologic disease were considered failures. NOS, not otherwise specified. a Discontinued treatment before scheduled time point.
patients, including underlying disease, prior antifungal treatments, pathogens and outcomes, are presented in Table 3 .
| In vitro susceptibility
Susceptibility testing results (CLSI and EUCAST MICs) were available from five patients in the rare mould IFD group and both patients in the non-Candida yeast IFD group ( 
| Safety
All patients in each group experienced TEAEs ( Table 5 ). The most common TEAEs overall (occurring in in ≥4 patients total) included gas- 
| D ISCUSS I ON
Among patients enrolled in the VITAL trial with IFD caused by rare or unspecified fungal species, more than 50% of all assessed patients were deemed an overall treatment success at the completion of isavuconazole treatment (EOT visit The current analysis is limited not only by the small numbers for each of the pathogens but also by the non-randomised nature of the study. Nevertheless, controlled studies for IFD caused by rare fungal species are currently not practical, 22, 52 and so evidence-based recommendations will continue to require amassing evidence from retrospective analyses, case reports, and openlabel studies for the near future. Towards that end, it is worth noting that another seven isavuconazole-treated patients from the VITAL trial had IFD caused by more than one pathogen and that included species that were closely related or identical to some in the current analysis (Fusarium spp., Scedosporium spp., Alternaria spp., Cladosporium spp.). 23 The SECURE study also included five patients with rare fungal pathogens closely related or identical to some in the current study (Fusarium spp., Scedosporium spp., Trichosporon spp.). 17 In an analysis of all patients with fusariosis or scedosporiosis from the VITAL and SECURE studies, one-third of each group of patients was considered treatment successes at EOT (fusariosis, 3/9; scedosporiosis, 1/3). 53 Thus, the data in the current analysis should help to provide context and serve as a useful baseline to which the results of future analyses and case reports can be added to allow a more definitive assessment of the efficacy and safety of isavuconazole for treatment of IFDs caused by various rare fungal species.
Taken together with results from the other analyses of the VITAL trial, 18, 21, 23 the current analysis suggests that isavuconazole may be useful for treatment of IFD caused by a range of rare fungal species.
If that is confirmed in further studies, it would suggest that isavuconazole might merit an expanded role as an antifungal treatment option. for their contributions to the design and execution of the study. 
ACK N OWLED G M ENTS
